Abstract
Allogeneic marrow transplantation offers curative therapy for pediatric patients with severe aplastic anemia. Over the past 4 decades, significant improvements in the long term outcome of patients treated with allogeneic marrow grafts have resulted from progress in the prevention and treatment of graft rejection and graft-versus-host disease (GVHD). Here we report the outcome of 149 pediatric patients, ages 2-19 years who received HLA-matched related marrow grafts for treatment of severe aplastic anemia between 1971 and 2009.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
